Many approved drugs have bioactive analogs with different target annotations

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 847-859

  Hu, Ye ^a   Lounkine, Eugen ^a,b   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

approved drugs; bioactive compounds; drug targets; matched molecular pairs; polypharmacology; structural relationships

Indexed keywords

ADENOSINE; ALIMEMAZINE; ALISKIREN; ARIPIPRAZOLE; BENZATROPINE; BIFONAZOLE; CINNARIZINE; CLOTRIMAZOLE; CYCLIZINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DRUG ANALOG; FLUNARIZINE; HALOPERIDOL; INDOMETACIN; METHDILAZINE; MIFEPRISTONE; MILNACIPRAN; MODAFINIL; PARACETAMOL; PHENELZINE; PROFENAMINE; PROMAZINE; PROMETHAZINE; RIMONABANT; SITAGLIPTIN; SULFANILAMIDE; UNINDEXED DRUG; VIDARABINE; VORINOSTAT; DRUG;

ARTICLE; DNA FINGERPRINTING; DRUG APPROVAL; DRUG DATABASE; DRUG FORMULATION; DRUG REPOSITIONING; DRUG STRUCTURE; DRUG TARGETING; LIMIT OF DETECTION; MATCHED MOLECULAR PAIR; MOLECULAR BIOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; REPRODUCIBILITY; STANDARDS; STATISTICS AND NUMERICAL DATA;

DATABASES, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903587648     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9621-8     Document Type: Article

References (39)

1. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol. 2006;24(7):805-15. doi:10.1038/nbt1228. (Pubitemid 44086621)
2. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197-206. doi:10.1038/nbt1284. (Pubitemid 46227119)
3. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90. doi:10.1038/nchembio.118.
4. Boran ADW, Iyengar R. Sys tems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010;13(3):297-309.
5. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10(2):130-7. doi:10.1038/nrc2787.
6. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321(5886):263-6. doi:10.1126/science.1158140. (Pubitemid 351989100)
7. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486(7403):361-7. doi:10.1038/nature11159.
8. Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2006;448(7154):645-6. doi:10.1038/448645a. (Pubitemid 47236844)
9. Xie L, Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol. 2012;52:361-79. doi:10.1146/annurev-pharmtox-010611-134630.
10. Jalencas X, Mestres J. On the origins of drug polypharmacology. MedChemComm. 2013;4(1):80-7. doi:10.1039/C2MD20242E.
11. Hu Y, Bajorath J. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment. AAPS J. 2013;15(1):104-11. doi:10.1208/s12248-012-9421-y.
12. Hu Y, Bajorath J. Compound promiscuity: what can we learn from current data? Drug Discov Today. 2013;18(13-14):644-50. doi:10.1016/j.drudis.2013.03. 002.
13. Hu Y, Bajorath J. High-resolution view of compound promiscuity. F1000Res. 2013;2:144. doi:10.12688/f1000research.2-144.v2 [v2; ref status: indexed, http://f1000r.es/1ig].
14. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness - the Achilles heel of drug-target networks. Nat Biotechnol. 2008;26(9):983-4. doi:10.1038/nbt0908-983.
15. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40(Database issue):D1100-7. doi:10.1093/nar/gkr777.
16. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Zhou Z, et al. PubChem's BioAssay database. Nucleic Acids Res. 2012;40(Database issue):D400-12. doi:10.1093/nar/gkr1132.
17. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011;39(Database issue):D1035-41.
18. Hu Y, Bajorath J. Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap. RSC Adv. 2012;2(8):3481-9. doi:10.1039/C2RA01345B.
19. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Rev Drug Discovery. 2007;6(11):881-90. doi:10.1038/nrd2445. (Pubitemid 350042396)
20. Wang J, Hou T. Drug and drug candidate building block analysis. J Chem Inf Model. 2010;50(1):55-67. doi:10.1021/ci900398f.
21. Müller G. Medicinal chemistry of target family-directed masterkeys. Drug Discov Today. 2003;8(15):681-91. doi:10.1016/S1359-6446(03)02781-8. (Pubitemid 36969999)
22. Sutherland JJ, Higgs RE, Watson I, Vieth M. Chemical fragments as foundations for understanding target space and activity prediction. J Med Chem. 2008;51(9):2689-700. doi:10.1021/jm701399f. (Pubitemid 351620791)
23. Renner S, van Otterlo WA, Dominguez Seoane M, Möcklinghoff S, Hofmann B, Wetzel S, et al. Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol. 2009;5(8):585-92. doi:10.1038/nchembio.188.
24. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem. 1996;39(15):2887-93. (Pubitemid 26251026)
25. Hu Y, Bajorath J. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs. ChemMedChem. 2010;5(2):187-90. doi:10.1002/cmdc.200900419.
26. Hu Y, Bajorath J. Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds. Eur J Med Chem. 2014;76:427-34. doi:10.1016/j.ejmech.2014.02.040.
27. Hu Y, Bajorath J. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J Chem Inf Model. 2010;50(12):2112-8. doi:10.1021/ci1003637.
28. Kenny PW, Sadowski J. Structure modification in chemical databases. In Chemoinformatics in Drug Discovery; Oprea TI, Ed.; Wiley-VCH: Weinheim, Germany, 2004; pp 271-285.
29. Hussain J, Rea C. Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets. J Chem Inf Model. 2010;50(3):339-48. doi:10.1021/ci900450m.
30. Hu X, Hu Y, Vogt M, Stumpfe D, Bajorath J. MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs. J Chem Inf Model. 2012;52(5):1138-45. doi:10.1021/ci3001138.
31. OEChem, version 1.7.7, OpenEye Scientific Software, Inc., Santa Fe, NM, USA. 2012. http://www.eyesopen.com.
32. Williams AJ, Harland L, Groth P, Pettifer S, Chichester C, Willighagen EL, et al. Open PHACTS: semantic interoperability for drug discovery. Drug Discov Today. 2012;17(21-22):1188-98. doi:10.1016/j.drudis.2012.05.016.
33. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17(5):436-7. (Pubitemid 24271517)
34. Sebban C, Tesolin-Decros B, Millan MJ, Spedding M. Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil. Br J Pharmacol. 1999;128(5):1055-63. doi:10.1038/sj.bjp.0702893. (Pubitemid 29512039)
35. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349-64. doi:10.2147/NDT.S. (Pubitemid 47215010)
36. Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab. 2003;4(2):105-29. doi:10.2174/1389200033489523. (Pubitemid 36443191)
37. Sundvik M, Kudo H, Toivonen P, Rozov S, Chen YC, Panula P. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J. 2011;25(12):4338-47. doi:10.1096/fj.11-188268.
38. Muraoka S, Miura T. Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003;92(2):100-4. doi:10.1034/j.1600-0773.2003.920207.x. (Pubitemid 36288310)
39. Hu Y, Bajorath J. Learning from 'big data': compounds and targets. Drug Discov Today. 2014;19(4):357-60. doi:10.1016/j.drudis.2014.02.004.